A Phase 1 interventional study of sevasemten and Verapamil in Healthy Subjects, sponsored by Edgewise Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-08.
Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this Phase 1 study of sevasemten are to:
Edgewise Therapeutics, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 1 (8%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose sevasemten administered on Day 1 under fasting conditions
Drug: sevasemten
Multiple doses of verapamil with a single dose of sevasemten under fasting conditions
Drug: sevasemten · Drug: Verapamil
Single dose sevasemten under high-fat fed conditions
Drug: sevasemten
single dose 10mg sevasemten administered orally
multiple doses 240mg verapamil
Pharmacokinetic
The area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) for sevasemten and metabolites administered with and without verapamil
Time frame: Up to 46 days of monitoring
Pharmacokinetic
The maximum observed concentration (Cmax) for sevasemten and metabolites administered with and without verapamil
Time frame: Up to 46 days of monitoring
Pharmacokinetic
The area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t) for sevasemten and metabolites under fasting and fed conditions
Time frame: up to 42 days of monitoring
Pharmacokinetic
The maximum observed concentration (Cmax) for sevasemten and metabolites under fasting and fed conditions
Time frame: up to 42 days of monitoring
Pharmacokinetic
The time to reach the maximum observed concentration (Tmax) for sevasemten and metabolites under fasting and fed conditions
Time frame: up to 42 days of monitoring
Pharmacokinetic
The lag time, time delayed between drug administration and the onset of absorption (Tlag), for sevasemten and metabolites under fasting and fed conditions
Time frame: up to 42 days of monitoring
Safety and Tolerability
Incidence of treatment emergent adverse events in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal chemistry test results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal hematology test results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal urinalysis test results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal heart rate results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal blood pressure results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal body temperature results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal respiratory rate results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Safety and Tolerability
Incidence of abnormal 12-lead ECG results in those with a single dose of sevasemten administered with and without verapamil and with or without food
Time frame: Up to 46 days of monitoring
Ran from Jan 2025 to primary completion in Feb 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sevasemten
Edgewise Therapeutics, Inc.